Antihistamínicos oftálmicos en la alergia ocular y el síndrome de ojo seco

  1. Jáuregui-Presa, Ignacio 123
  2. Arrien-de Lecea, Ángel 2
  3. Galán-Gimeno, Cristina 2
  4. Sánchez-de Vicente, Javier
  5. Pérez-Escalera, Lucy-Mónica 2
  6. Gamboa-Setién, Pedro 123
  1. 1 Instituto de Investigación Biobizkaia. Grupo de Inmunopatología. Barakaldo, España
  2. 2 Servicio de Alergia. Hospital Universitario Cruces. Barakaldo, España
  3. 3 Grupo IMQ. Cuadro médico. Bilbao, España
Show affiliations +
Journal:
Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

ISSN: 0304-4858,  2173-2302

Year of publication: 2024

Volume: 121

Issue: 1

Pages: 30-38

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios

Abstract

Allergic conjunctivitis and dry eye syndrome are very prevalent disorders, frequently associated and underdiagnosed. Diagnosis of allergic conjunctivitis is clinical, and should include an allergological study allowing detection and control of involved allergens. Treatment of conjunctivitis includes hygiene and avoidance measures, allergen-specific immunotherapy when indicated, and a stepwise pharmacological treatment, with ocular antihistamines as the first line of treatment. In antihistamine eye drops, latest generation active ingredients are preferred, with a more selective action, less penetration into the CNS, fewer interactions and fewer anticholinergic effects than older, classic antihistamines. It is crucial to use preservative-free eye drops to maintain the integrity of the ocular surface and prevent the onset or worsening of dry eye syndrome. The association of lubricating agents to the formulations, such as hyaluronic acid, also helps to prevent ocular dryness and may also increase the bioavailability of the active ingredient. To achieve the best patient acceptance and adherence, whenever possible it is advisable to use eye drops that permit single daily dose treatment regimens.

Bibliographic References

  • Zubeldia JM, Baeza ML, Chivato T, Jáuregui I, Senent CJ. El libro de las Enfermedades Alérgicas. – 2nd ed. – Bilbao: Fundación BBVA, 2021. p. 15
  • Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy 2012; 67: 1327–1337.
  • Patel DS, Arunakirinathan M, Stuart A, Angunawela R: Allergic eye disease. BMJ. 2017; 359:j4706
  • Leonardi A, Modugno RL, & Salami E. Allergy and Dry Eye Disease. Ocul Immunol Inflamm. 2021;29(6):1168-1176
  • Singh N, Diebold Y, Sahu SK, Leonardi A. Epithelial barrier dysfunction in ocular allergy. Allergy. 2022; 77:1360-1372.
  • Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: Diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124(2):118-34.
  • Sánchez-Hernández MC, Montero J, Rondón C, Benítez del Castillo JM, Velázquez E, Herreras JM, et al. Consensus document on allergic conjunctivitis (DECA). J Investig Allergol Clin Immunol. 2015;25(2):94-106
  • Sánchez-Hernández MC, Navarro AM, Colás C, Del Cuvillo A, Sastre J, Mullol J, et al. Validation of the DECA criteria for allergic conjunctivitis severity and control. Clin Transl Allergy. 2020; 10:43.
  • Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No.: CD009566. DOI: 10.1002/14651858.CD009566.pub2.
  • Bilbao Laiseca A. Colirios. Panorama Actual Med. 2018; 42 (414): 602-608
  • Herrero-Vanrell R, Jáuregui Presa I, Leceta Bilbao A, Montero Iruzubieta J. Fundamental aspects and relevance of components in antihistamine eye drops. J Investig Allergol Clin Immunol 2023; 33(6): 431-438
  • Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol. 2000;27(7):558-562.
  • Goldstein MH, et al. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond) 2022; 36(2): 361–368
  • Leonardi A. et al. Management of ocular allergy. EAACI Position paper- Allergy. 2019; 74:1611– 1630
  • Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798
  • Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol. 2010;20(2):257-264.
  • Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020;20(4):414-420.
  • Eiwegger T, Simons ER, Akdis CA. Histamine and antihistamines. En Middleton’s Allergy Principles & Practice, 9th Ed, Elsevier 2019
  • Yanai K, Zhang D, Tashiro M, et al. Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf. 2011; 10:613-622.
  • Jáuregui I, Ferrer M, Montoro J, Dávila I, Bartra J, del Cuvillo A, et al. Antihistamines in drivers, aircrew and occupations of risk. J Investig Allergol Clin Immunol. 2013;23 Suppl 1:27-34.
  • Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32: 489-498.
  • Church MK, Collinson AD, Okayama Y. H1-receptor antagonists: antiallergic effects in vitro. En: Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker; 1996. p. 117-144.
  • Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020; 16:5
  • Secchi A, Leonardi A, Discepola M, Deschenes J, Abelson MB. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swe
Data source: Dialnet